PI3K inhibitors in trastuzumab-resistant HER2-positive breast cancer cells with PI3K pathway alterations.

作者：Wei‐Pang Chung, Wei-Lun Huang, Chun‐Hui Lee, Hui‐Ping Hsu, Wanling Huang, You‐Yu Liu, Wu‐Chou Su · 发表于：PubMed · 年份：2022 · 被引用次数：32 · 研究领域：HER2/EGFR in Cancer Research、PI3K/AKT/mTOR signaling in cancer、Advanced Breast Cancer Therapies

effects of alpelisib plus trastuzumab were tested and confirmed in a mouse model, showing the combination strategy offered the best opportunity to achieve tumor volume reduction. With known safety profiles, this cytotoxic chemotherapy-free regimen warrants further attention as a biomarker-driven strategy for treating HER2-positive breast cancer.